Related Experiment Video
Updated: Feb 26, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Sandrine Guillard1, Paulina Kolasinska-Zwierz1, Judit Debreczeni2
1Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.
Abstract:
Ras mutations are the oncogenic drivers of many human cancers and yet there are still no approved Ras-targeted cancer therapies. Inhibition of Ras nucleotide exchange is a promising new approach but better understanding of this mechanism of action is needed. Here we describe an antibody mimetic, DARPin K27, which inhibits nucleotide exchange of Ras. K27 binds preferentially to the inactive Ras GDP form with a Kd of 4 nM and structural studies support its selectivity for inactive Ras. Intracellular expression of K27 significantly reduces the amount of active Ras, inhibits downstream signalling, in particular the levels of phosphorylated ERK, and slows the growth in soft agar of HCT116 cells. K27 is a potent, non-covalent inhibitor of nucleotide exchange, showing consistent effects across different isoforms of Ras, including wild-type and oncogenic mutant forms.
Insights
Researchers developed DARPin K27, a novel antibody mimetic targeting Ras proteins. This inhibitor shows promise for cancer therapy by blocking Ras nucleotide exchange and downstream signaling, including in mutant Ras forms.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Ras mutations drive numerous human cancers, yet targeted therapies remain limited.
- Inhibiting Ras nucleotide exchange is a potential therapeutic strategy requiring further mechanistic understanding.
Purpose of the Study:
- To describe DARPin K27, an antibody mimetic designed to inhibit Ras nucleotide exchange.
- To evaluate the efficacy and specificity of K27 as a Ras inhibitor.
Main Methods:
- Characterization of K27 binding affinity and selectivity for Ras GDP.
- Intracellular expression of K27 in HCT116 cells.
- Assessment of downstream signaling, including phosphorylated ERK levels.
- Evaluation of cell proliferation in soft agar assays.
Main Results:
- K27 demonstrated high affinity (4 nM Kd) for the inactive Ras GDP form, with selectivity confirmed by structural studies.
- Intracellular K27 expression reduced active Ras levels and inhibited downstream signaling pathways, notably phosphorylated ERK.
- K27 treatment slowed the growth of HCT116 cells in soft agar.
- The inhibitor showed consistent efficacy across various Ras isoforms, including wild-type and oncogenic mutants.
Conclusions:
- DARPin K27 is a potent, non-covalent inhibitor of Ras nucleotide exchange.
- K27 effectively reduces active Ras signaling and inhibits cancer cell growth.
- This antibody mimetic represents a promising new avenue for developing Ras-targeted cancer therapies.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Directionality of Nuclear Transport

